Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients

Stopped when realized that the target 60% of patients with SVR was no more achievable

Conditions

• HCV Recurrence After Liver Transplantation

Interventions

• DRUG: Silibinin
• DRUG: Placebo

Sponsor

Rottapharm